Status:
COMPLETED
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Lead Sponsor:
National Jewish Health
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
HIV
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether or not adding Raltegravir to a fully suppressive antiretroviral regimen will assist in reducing HIV-1 associated chronic inflammation and increase the...
Eligibility Criteria
Inclusion
- At least 18 years of age
- HIV-positive by Western blot or viral load
- Viral load \< 400 copies/ml
- CD4+ T-lymphocyte count less than 350 cells/mm3 or change in CD4+ T-lymphocyte count \< 100 cells/mm3 for at least one year on stable HAART with viral load \< 400 copies/ml for the same period of time
Exclusion
- CD4+ T-lymphocyte count greater than or equal to 350 cells/mm3 or rise in CD4+ T-lymphocyte count greater than or equal to 100 cells/mm3 within one year of study entry
- Viral load \> 400 copies/ml
- Allergy or resistance to raltegravir
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00738569
Start Date
July 1 2008
End Date
February 1 2011
Last Update
January 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Jewish Health
Denver, Colorado, United States, 80206